A
Aminah Jatoi
Researcher at Mayo Clinic
Publications - 440
Citations - 15796
Aminah Jatoi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 46, co-authored 404 publications receiving 12708 citations. Previous affiliations of Aminah Jatoi include University of Texas Health Science Center at San Antonio & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Colorectal Cancer, Crohn-Like Lymphoid Reactions, Survival - And the Power of a Good Cup of Coffee!
Mojun Zhu,Aminah Jatoi +1 more
TL;DR: This article reported a strong association between coffee consumption and pancreatic cancer and other studies have cited uncontrolled for confounders to explain this earlier, unexpected observation, drawing very different conclusions of their own: coffee now seems to confer health benefits, reduce cancer risk, and improve cancer outcomes.
Journal ArticleDOI
Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.
Rachel A. Freedman,Drew K. Seisler,Jared C. Foster,Jacqueline M. Lafky,Gretchen Kimmick,Aminah Jatoi,Hyman B. Muss,Harvey J. Cohen,Jeanne S. Mandelblatt,Eric P. Winer,Clifford A. Hudis,C. Cirrincione,Alvaro Moreno-Aspitia,Arti Hurria +13 more
TL;DR: The proportion of enrolled pts aged 65+ significantly increased with time in adjuvant/neoadjuvant trials, but decreased slightly in metastatic trials, and similar trends were seen for pts aged 70+, but were statistically significant for adjUvant trials only.
Journal ArticleDOI
Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma
Samuel O. Antwi,William R. Bamlet,Richard M. Cawthon,Kari G. Rabe,Brooke R. Druliner,Hugues Sicotte,Aminah Jatoi,Amit Mahipal,Lisa A. Boardman,Ann L. Oberg,Gloria M. Petersen +10 more
TL;DR: Shorter treatment-naïve LTL is associated with poorer overall survival of patients with incident PDAC, and peripheral blood LTL might be a prognostic marker for PDAC.
Journal ArticleDOI
Consumer beware: a systematic assessment of potential bias in the lay electronic media to examine the portrayal of "PARP" inhibitors for cancer treatment.
TL;DR: Healthcare providers should be aware of the foregoing when discussing PARP inhibitors—and perhaps other novel therapies—with cancer patients.
Journal ArticleDOI
Toxicities and Related Outcomes of Elderly Patients (pts) (≥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611)
Michael Tallarico,Jared C. Foster,Drew K. Seisler,Jacqueline Lafky,Arti Hurria,Aminah Jatoi,Harvey J. Cohen,Hyman B. Muss,Nancy L. Bartlett,Bruce D. Cheson,Sin-Ho Jung,John C. Byrd,John P. Leonard,Chadi Nabhan +13 more
TL;DR: Several clinical and disease-related factors were identified as potential predictors of developing grade 3 and/or 4 heme and non-hem toxicities and a prognostic model is being constructed to predict toxicities in these under-studied pts to guide management and monitoring.